Contemporary studies of dual HER2-targeted therapy with the combinations of trastuzumab–pertuzumab and trastuzumab–lapatinib have demonstrated promising initial results in metastatic HER2-amplified CRC, rates of response in the region of approximately 30% (114, 115). This evidence concerns the gene ERBB2 and colorectal carcinoma.